When entering tech partnerships, understanding confidentiality agreements is crucial to safeguarding your intellectual property and ensuring smooth collaboration. You need to be proactive in identifying the sensitive information that requires protection and establishing clear terms with your partners. By navigating these agreements thoughtfully, you not only protect your innovations but also build trust and transparency within your business relationships. Discover practical strategies to secure your interests and set your technology projects up for success.

When you take your business into international markets, protecting your intellectual property becomes more complex but also more crucial. You need robust IP protection strategies to defend your patents, trademarks, and confidential information from infringement and misuse on a global scale. This blog guides you through practical steps you can take to secure your international intellectual property as your company pursues global business expansion. By understanding the risks and implementing proactive measures, you can confidently grow your business while minimizing potential legal and financial setbacks.

As a tech startup founder, safeguarding your innovative ideas is crucial to maintaining your competitive advantage and avoiding costly legal setbacks. By understanding the essentials of intellectual property protection and implementing a robust IP strategy, you can proactively reduce tech startup legal risks and prevent infringement before it becomes a threat. This article guides you through practical steps to secure your intellectual assets, helping you steer clear of expensive disputes and ensuring your business is positioned for long-term success. Discover how a strategic approach to intellectual property can empower your growth and protect your unique value in the marketplace.

Are you a startup founder looking to protect your groundbreaking ideas? In our latest post, “How to Safeguard Your Startup’s Ideas With Smart IP Strategies,” you’ll learn essential steps for effective intellectual property protection. We guide you through actionable startup IP strategy tips and offer business legal advice tailored to the unique challenges startups face. Don’t leave your innovations vulnerable—discover how to secure your competitive advantage and avoid costly legal disputes as you grow your business.

Unlock the full potential of your business with a robust intellectual property strategy tailored for long-term growth. In this insightful article, you will learn how strategic IP planning can protect your innovations, drive business growth, and deliver a competitive edge—especially for Canadian businesses operating in the technology and pharmaceutical sectors. Discover actionable steps to align your IP approach with your commercial goals, safeguard your assets, and thrive in an evolving marketplace. Whether you are looking to expand locally or globally, this guide will help you build a resilient foundation for sustained success.

Discover why a robust intellectual property strategy is essential for growing Canadian businesses. Whether you are a startup or an established company in Toronto, Hamilton, Kitchener, Waterloo, Ottawa, or elsewhere in Canada, protecting your business IP can be the key to sustainable success. In this post, you will learn how working with a knowledgeable Toronto IP lawyer can help you stay ahead of the competition, secure your innovations, and navigate the complexities of Canadian business law. Empower your business to expand confidently both locally and globally by understanding the value of intellectual property for startups and established enterprises alike.

We are delighted to announce the launch of our new website!

New Website Coming Soon!
We are currently revamping our website. Our new website will be interactive and mobile friendly! Watch this space for updates. Just a few more weeks to go!

Hot off the press... the US Supreme Court has decided i4i v. Microsoft. At a quick glance: s.282 of the US Patent Act requires a party alleging invalidity to show it by "clear and convincing" evidence. Also at a quick glance, this applies whether or not a piece of prior art was considered by the patent examiner.

I have been focused on the effect CETA would have on patents and pharmaceuticals. Of course, there's lots of other stuff in CETA, including copyright. Michael Geist has posted a copy of his comments to the Standing Committee on International Trade HERE.

Sanofi Pasteur, which makes vaccines, is planning to expand its operations in Toronto.

Norman Siebrasse of UNB law, whom I've written papers with in the past and I think has all sorts of good things to say about patents, now has his own blog:

Go read the post on this topic at Sufficient Description. It brings up an interesting topic - when courts review the validity of patents, does it have to comply with administrative law principles, or is it its own standard? Professor Siebrasse notes that Gauthier J. in Eli Lilly / cefaclor 2009 FC 991 essentially ruled that Supreme Court musing on this point was wrong, and agrees with Gauthier J.

I always think its the beginning of the end of the line for an idea or concept when people start publicly making fun of it. So THIS ARTICLE in Slate Magazine about the Light and Warburton study on drug R&D costs is interesting. The article concludes:

I don’t want to be a blogger that leaves negative comments unaddressed in the comments section, so I want to bring up two good comments to my post on the Light and Warburton article.

First – actually, I shouldn’t have said anything about 11% being a high cost of capital. I certainly don’t keep track of what a reasonable cost is. It could be 20%, for all I know ;)

Here is a link to a recent paper (pdf) by Donald Light and Rebecca Warburton titled "Demythologizing the high costs of pharmaceutical research", (BioSocieties, February 2011) which systematically critiques the estimates of pharmaceutical-related R&D costs routinely promoted by the research-based pharmaceutical companies. As put by Andre Picard in a recent Globe and Mail article, "Drug R&D costs are less than estimated - so why the high prices?",

One risk of blogging is that I often think of something just after pressing "Publish Post" ;)

There have been stories coming out of Ottawa saying the CETA trade deal is in trouble.

First, there is this from Paul Wells:
http://www2.macleans.ca/2011/02/17/free-trade-with-europe-never-mind/#more-173556

An article by Neil Reynolds in the Globe and Mail discussing Canada's relative performance in terms of patent applications filed. The article questions Canada's performance on a per capita basis:

Hot off the presses - Aidan Butler of Gilbert's, "a raffish man of mystery" is named one off Canada's 30 most eligible bachelors!